Covaxin

Covaxin

Part of: GS-III- S&T (PT-MAINS-PERSONALITY TEST)

The Central Drugs Standard Control Organisation (CDSCO) has granted approval to Bharat Biotech to conduct human clinical trials for ‘Covaxin’, making it the first indigenous Covid-19 vaccine candidate to receive this approval.

Covaxin has been developed by the company Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). It is an inactivated vaccine manufactured in the company’s Bio-Safety Level 3 (BSL-3) High Containment facility located in Hyderabad (Telangana).
The permission was granted after the company submitted results from pre-clinical studies of the vaccine that demonstrated its safety and immune response. Phase I and II clinical trials will start across India in July 2020.

ImpPoints

Clinical trials in humans are classified into three phases: phase I, phase II and phase III and in certain countries formal regulatory approval is required to undertake any of these studies.
The phase I clinical studies carry out initial testing of a vaccine in small numbers (e.g. 20) of healthy adults, to test the properties of a vaccine, its tolerability, and, if appropriate, clinical laboratory and pharmacological parameters. Phase I studies are primarily concerned with safety.
Phase II studies involve larger numbers of subjects and are intended to provide preliminary information about a vaccine’s ability to produce its desired effect (usually immunogenicity) in the target population and its general safety.
Extensive phase III trials are required to fully assess the protective efficacy and safety of a vaccine. The phase III clinical trial is the pivotal study on which the decision on whether to grant the licence is based and sufficient data have to be obtained to demonstrate that a new product is safe and effective for the purpose intended.
An application for market authorization may be submitted to the National Regulatory Authority (NRA) on the basis of the data from phase III testing and if approved, the vaccine then becomes commercially available in that particular country.
- The Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare is the National Regulatory Authority (NRA) of India.
According to the World Health Organisation (WHO), out of 200 Covid-19 vaccine candidates, 15 have entered clinical trials.
- AstraZeneca is the world’s leading Covid-19 vaccine candidate and has reached the final stage in terms of development. It is being developed by researchers at the University Of Oxford (UK).
- US Firm Moderna’s vaccine (MRNA-1273) will go into phase III clinical trials in July.

Source: TH

Join Our Telegram

Drugs and Clinical Trials Rules, 2019

Integrated Disease Surveillance Programme

Pradhan Mantri Suryodaya Yojana

06 Feb, 24
SHARE

Recently, Prime Minister announced Pradhan Mantri Suryodaya Yojana under which 1 crore households will get rooftop solar power systems. India’s Status of Current Solar Capacity India currently stands at 4th place globally in solar power capacity. As per Ministry of New an

Foreign Contribution Regulation Act (FCRA)- NGO

06 Feb, 24
SHARE

The Foreign Contribution Regulation Act, 2010 (FCRA) registration of two prominent non-governmental organisations (NGOs) — Centre for Policy Research (CPR) and World Vision India (WVI) have been cancelled this month. What is FCRA? Key provisions of FCRA, 2010 Key aspects Description

Voice clone-AI

06 Feb, 24
SHARE

Voice clone fraud has been on the rise in India. AI voice cloning – It is the process of creating a synthetic replica of a person’s voice through machine learning and speech synthesis technology.It is called as voice deepfakesor audio deepfakes. Objective – To achieve a high level of na

Science communication- how to promote

06 Feb, 24
SHARE

Steps taken by India to promote Science Communication Publications and Information Directorate (PID) - An organisation under Council of Science and Industrial Research (CSIR) established in 1951 for publishing and disseminating scientific information in India. National science magazines- The PI

Universal Basic Income (UBI)- Analysis

05 Feb, 24
SHARE

Universal Basic Income (UBI) can strengthen welfare architecture and unlock the nation’s latent demographic potential. UBI - It is an income support mechanism typically intended to reach all or a very large portion of the population regardless of their earnings or employment status. Objective- To provide enough to co